Exploring The Clinical Significance of Serum Angiopoietin-2 In Breast Cancer Patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Abeer I Abd Elmagid ◽  
Hala Abdel Al ◽  
Wessam El Sayed Saad ◽  
Seham Kamal Mohamed
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Tnm Staging ◽  
Control Group ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Female Patients ◽  
Significant Difference ◽  
Angiopoietin 2

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p < 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p > 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p > 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.

scholarly journals Effect of Flavor Enhancement on the Appreciation of Food in Breast Cancer Patients Undergoing Chemotherapy

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 320-320
Author(s):  
Kenza Drareni ◽  
Moustafa Bensafi ◽  
Helene Lusson ◽  
Damien Vansteene ◽  
Agnès Giboreau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hierarchical Cluster ◽  
Cross Sectional Study ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Funding Sources ◽  
Significant Difference ◽  
The Impact

Abstract Objectives Given the influence of sensory signals on food intake regulation and the subsequent nutritional status, it is important to reduce the impact of commonly observed smell and taste alterations on the pleasure of eating during chemotherapy. This study aimed to examine the effect of various types of flavor enhancement on the appreciation of an appetizer by a group of patients undergoing chemotherapy. Methods Five eggplant appetizers with no seasoning (REF) or enhanced with either salt, lemon, garlic or cumin were developed. In this cross-sectional study, 36 healthy female subjects (age 58 ± 7 y) (control group) and 84 breast cancer patients (age 56 ± 11 y) treated with chemotherapy were recruited. A hierarchical cluster analysis based on patients' self-reported smell and taste abilities classified the patients in two groups: the ‘unaltered, (high sensory abilities) n = 49’ and the ‘altered, (poor sensory abilities), n = 35’ group. Participants tasted and assessed the appreciation of the reference appetizer on a visual analog scale and performed a randomized comparative liking task, by rating the appreciation for each flavor-enhanced appetizer relative to the REF (one-sample t-test). Results There was no significant difference in the appreciation of the REF appetizer between the three groups (P > 0.05). In the comparative liking task, the control group rated similarly the appreciation between the flavor-enhanced and the REF appetizers except for the cumin-enhanced appetizer, which was appreciated significantly more than the REF (P < 0.001). Patients in both ‘altered’ and ‘unaltered’ groups appreciated similarly the cumin appetizer (P > 0.05), more the salt and garlic-enhanced appetizers (P ≤ 0.001, P = 0.005, respectively) and significantly less the lemon-enhanced appetizer relative to the REF (P = 0.029), confirming a tendency for patients to reject acid-flavored foods. Conclusions The salt and garlic enhancements were appreciated by the patients independent of the stage of chemotherapy or the severity of smell and taste alterations. Flavor enhancement seems a good strategy to maintain the pleasure of eating in patients undergoing chemotherapy. Further research is still needed on the appreciation and intake of a complete meal (starter, main course, dessert). Funding Sources APICIL and ELIOR groups.

Machine learning methods with salivary metabolomics for breast cancer detection.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3135-3135
Author(s):  
Takeshi Murata ◽  
Takako Yanagisawa ◽  
Toshiaki Kurihara ◽  
Miku Kaneko ◽  
Sana Ota ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Learning Methods ◽  
Validation Data ◽  
Machine Learning Methods ◽  
Significant Difference

3135 Background: Saliva is non-invasively accessible and informative biological fluid which has high potential for the early diagnosis of various diseases. The aim of this study is to develop machine learning methods and to explore new salivary biomarkers to discriminate breast cancer patients from healthy controls. Methods: We conducted a comprehensive metabolite analysis of saliva samples obtained from 101 patients with invasive carcinoma (IC), 23 patients with ductal carcinoma in situ (DCIS) and 42 healthy controls, using capillary electrophoresis and liquid chromatography with mass spectrometry to quantify hundreds of hydrophilic metabolites. Saliva samples were collected under 9h fasting and were split into training and validation data. Conventional statistical analyses and artificial intelligence-based methods were used to access the discrimination abilities of the quantified metabolite. Multiple logistic regression (MLR) model and an alternative decision tree (ADTree)-based machine learning methods were used. The generalization abilities of these mathematical models were validated in various computational tests, such as cross-validation and resampling methods. Results: Among quantified 260 metabolites, amino acids and polyamines showed significantly elevated in saliva from breast cancer patients, e.g. spermine showed the highest area under the receiver operating characteristic curves (AUC) to discriminate IC from C; 0.766 (95% confidence interval [CI]; 0.671 – 0.840, P < 0.0001). These metabolites showed no significant difference between C and DICS, i.e., these metabolites were elevated only in the samples of IC. The MLR yielded higher AUC to discriminate IC from C; 0.790 (95% CI; 0.699 – 0.859, P < 0.0001). The ADTree with ensemble approach showed the best AUC; 0.912 (95% CI; 0.838 – 0.961, P < 0.0001). In the comparison of these metabolites in the analysis of each subtype, seven metabolites were significantly different between Luminal A-like and Luminal B-like while, but few metabolites were significantly different among the other subtypes. Conclusions: These data indicated the combination of salivary metabolomic profiles including polyamines showed potential ability to screening breast cancer in a non-invasive way.

scholarly journals Intelligent Optimization of Treatment of Acupuncture based on Modern Data Analysis (Preprint)

2020 ◽  
Author(s):  
Xiujun Wang
Keyword(s):  
Breast Cancer ◽  
Data Analysis ◽  
Acupuncture Therapy ◽  
Cancer Patients ◽  
Postoperative Treatment ◽  
Major Surgery ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Experimental Group

BACKGROUND Background: Postoperative Fatigue Syndrome (POFS) occurs in almost every patient who has undergone major surgery. With the ever-increasing attention of people on rehabilitation treatment, POFS has received unprecedented attention. OBJECTIVE Objective: Based on modern data analysis, acupuncture treatment is optimized intelligently, and its efficacy in breast cancer patients with POFS is explored. METHODS Methods: In this study, the acupuncture and moxibustion in traditional Chinese medicine were combined to optimize the formation of warm acupuncture therapy, and then the research on warm acupuncture was optimized using modern data analysis methods. At first, the statistics of personal information and operation of 60 patients with breast cancer was carried out. The statistical results were analyzed by rank sum test and independent sample T test. The Visual Analogue Scale (VAS), Brief Profile Of Mood State (BPOMS), and Identity-Consequence Fatigue Scale (ICFS) were utilized to analyze the fatigue degree, mental state, and fatigue state of the patients. RESULTS Results: There was no significant difference in age (U = 473.34, P = 0.583) and education level (U = 479.20, P = 0.613) between the experimental group and the control group (P > 0.05), which were comparable. Compared with the control group, the VAS values of the experimental group on the 3rd day (P = 043), 7th day (P = 0.039), and 14th day (P = 0.030) of postoperative treatment were significantly reduced, with significant differences (P < 0.05). In the experimental group, the BPOMS values on the 3rd day (P = 0.042), 7th day (P = 0.035), and 14th day (P = 0.031) of postoperative treatment were significantly reduced, with significant differences (P < 0.05). The ICFS values of the experimental group on the 3rd day (P = 046), 7th day (P = 0.037), and 14th day (P = 0.031) of postoperative treatment were significantly reduced, with significant differences (P < 0.05). The variance of transferrin levels was uniform on the 7th day after operation (F = 0.679, P = 0.433 > 0.005), with a significant difference (T = -2.985, P = 0.008 < 0.05). CONCLUSIONS Conclusions: Warm acupuncture therapy could effectively improve the POFS of breast cancer patients, which was a safe and effective treatment. CLINICALTRIAL

scholarly journals Effectiveness of yoga on anxiety, depression and stress level of breast cancer patients undergoing chemotherapy

2017 ◽  
Vol 6 (1) ◽  
pp. 74
Author(s):  
Kamli Prakash ◽  
Sunil Saini
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Stress Level ◽  
Controlled Trial ◽  
Control Group ◽  
Research Approach ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Anxiety Depression ◽  
Experimental Group

Background: Breast cancer has ranked number one cancer among Indian females. Women undergoing chemotherapy experience many side effects including alteration in their body image. The present study assessed effectiveness of yoga on anxiety, depression and stress level of breast cancer patients undergoing chemotherapy.Methods: Quantitative Research approach and Randomized Clinical Controlled Trial with Time series design was adopted in the present study. The consecutive sampling technique was done to recruit 100 breast cancer patients fulfilling the eligibility criteria. Recruited patients were randomized to control (N=52) and experiment (N=48) groups by concealed randomization. Written informed consent was taken from each participant. Baseline data was collected during cycle one by using Anxiety depression and stress scale. The patients in the experimental group were taught Diaphragmatic breathing, systematic relaxation and alternate nostril breathing and Joints and Gland neck and shoulder exercises, and were instructed to practice them twice daily at home. They were supervised in practicing these when they received second, third, fourth, fifth and sixth cycles of chemotherapy. Participants in control group received routine care. Data was again collected after 21 days during second, third, fourth, fifth and sixth cycles of chemotherapy.Results: Analysis revealed that at the baseline breast cancer patients in control and experimental group were homogenous in terms of their Sociodemographic and anxiety depression and stress scores. After the yoga intervention the experimental group showed statistically significant difference in anxiety scores from control group during second, third and sixth cycles (p 0.01, p 0.02, p 0.02), in depression score during the second, third, fourth, fifth and sixth cycles (p 0.02, p 0.02, p 0.02, p 0.001, p 0.000), and in stress scores during third cycle (p 0.01) of chemotherapy.Conclusions: On the basis of findings of the study it was concluded that yoga was effective in reducing the anxiety, depression and stress of breast cancer patients undergoing chemotherapy. Therefore, it is recommended as complementary therapy for patients receiving treatment for cancer. 

scholarly journals The influences of preoperative metformin on immunological factors in early breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14182-e14182
Author(s):  
Takahiro Takahiro ◽  
Tadahiko Shien ◽  
Naruto Taira ◽  
Mariko Kochi ◽  
Takayuki Iwamoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Control Group ◽  
Metformin Treatment ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Immunological Factors ◽  
Risk Of Cancer

e14182 Background: Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and some reports have suggested that metformin may reduce cancer risk. Diabetics treated with metformin have a 23% reduction in the risk of cancer, including breast cancer. In addition, it is reported that the breast cancer patients with metformin treatment for diabetes showed favorable prognosis compared with those without metformin treatment. However, the mechanism underlying the positive effects of metformin on cancer treatment remains unclear. Methods: We conducted a prospective study to evaluate the effect of preoperative metformin on early breast cancer patients. The patients took a daily dose of metformin orally for 7 to 21 days before surgery. We evaluated the effects on immunological factors (TILs, CD4+, CD8+, PD-L1 and ALDH1) by comparing core needle biopsies (CNB) obtained before surgery with surgical specimens. Results: Seventeen breast cancer patients were enrolled in this prospective study and administered metformin before surgery, during the period from January to December 2016. We analyzed 59 patients who received surgery during the same period as a control group. In the control group, there was no significant difference in TILs between CNB and surgical specimens (Rs = 0.63). In the metformin group, TILs were negative in CNB and surgical specimens of 15 (88%) and 8 (48%) cases, low in 2 (12%) and 8 (48%), and intermediate in 0 and 1 (6%), respectively. These TILs increases were confirmed in 5 (29%) patients (p = 0.09), while a decrease was confirmed in 2 (12%). The expressions of CD4+ and CD8+ by TILs were increased in 41% and 18% of surgical specimens, respectively. (p = 0.02, p = 0.09) However, there was no statistically significant difference in these immunological factors and PD-L1 or ALDH1 expression between before and after metformin. Conclusions: In our small cohort, preoperative metformin administration shows positive impact on CD4 positive lymphocytes significantly and has tendency of increasing both TILs and CD8 positive lymphocytes. However, we should keep in mind that our sample size is small. Further study is necessary to uncover the mechanisms of favorable effects of metformin on breast cancer patients.

scholarly journals The role of serum 25-hydroxyvitamin D, ionized calcium and phosphorus in breast cancer females: A case-control study

2015 ◽  
Vol 4 (2) ◽  
pp. 228 ◽  
Author(s):  
Nadia Abd El Moneim ◽  
Taha Hewala ◽  
Mona Rashad ◽  
Yousria Moussa ◽  
Nehal Abu-Samra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Ionized Calcium ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Serum Ionized Calcium ◽  
Group Serum

<p><strong>Aim:</strong> To evaluate the diagnostic and prognostic value of serum 25- hydroxyvitamin D (25(OH) D), ionized calcium and phosphorus in comparison with serum CA15.3 as the most commonly used breast cancer marker.</p><p><strong>Participants and methods:</strong> This study was conducted on 45 breast cancer female patients with recently detected breast cancer before surgery and 45 apparently healthy female controls of matched age, menstrual and socioeconomic status as breast cancer patients group. Serum 25(OH) D, ionized calcium, phosphorus and CA15.3 were measured using ready-for-use commercially available kits.</p><p><strong>Results:</strong> Serum levels of 25(OH) D and ionized calcium in the breast cancer patients group were significantly lower than those of the control group, while serum levels of phosphorus and CA15.3 in breast cancer patients group were significantly higher than those of the control group. The area under the ROC curve for serum ionized calcium (81.7%) was significantly greater than that of 25(OH) D (75.3%), CA 15.3 (70.1%) and phosphorus (62.8%). The odd’s ratio of vitamin D was 0.0937 (95% CI=0.0311-0.2823), of ionized calcium was 0.0464 (95% CI=0.015-0.141) and of phosphorus was 2.6801(95% CI=1.1269- 6.3742) in breast cancer patients group. Serum phosphorus was significantly correlated with age and menopausal status of breast cancer patients.</p><p><strong>Conclusion:</strong> Our results suggest that serum ionized calcium and 25(OH) D were superior to serum CA15.3 and phosphorus for prediction of breast cancer. In addition, our results indicate that 25 (OH) D and calcium may decrease the risk for breast cancer incidence, while phosphorus may increase this risk. None of the assayed biomarkers has a prognostic role in breast cancer.</p>

scholarly journals S100A14 serum level and its correlation with prognostic factors in breast cancer

2020 ◽  
Vol 32 (1) ◽  
Author(s):  
Noor Al-Ashkar ◽  
Almoutassem Billah Zetoune
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Metastasis ◽  
Prognostic Significance ◽  
Serum Levels ◽  
Control Group ◽  
Study Group ◽  
Strong Positive Correlation ◽  
Breast Cancer Patients ◽  
Cross Sectional

Abstract Background Breast cancer is the most commonly occurring cancer in women worldwide. S100A14 is a novel important member of S100 proteins family. Its importance is due to its role in tumorigenesis and metastasis process. In this study, we aimed to determine serum levels of S100A14 protein in breast cancer patients and healthy individuals to know if it can be suggested as a new biomarker for breast cancer and to reveal whether it is correlated with cancer pathological features. Methods This cross-sectional study was performed in two groups: study group contains 46 breast cancer patients (29 metastatic and 17 non-metastatic) and control group contains 22 healthy women. Enzyme-linked immunoabsorbent assay was performed to determine S100A14 protein levels in samples. Pathological data were obtained for each patient. The data were statistically analyzed using Kruskal-Wallis H, Mann-Whitney U, and Spearman correlation tests. Results S100A14 serum levels were elevated in study group compared with control group (P < 0.05). S100A14 serum levels were significantly increased in distant breast cancer patients compared with regional breast cancer patients (P = 0.001). There was a strong positive correlation between serum S100A14 level and tumor grade (rs = 0.713, P < 0.001). Conclusion Our study indicated that S100A14 serum levels are elevated in breast cancer patients compared with control individuals. High S100A14 serum levels were correlated with poor tumor differentiation so it might have a prognostic significance for breast cancer tumors. The elevation of S100A14 levels in distant breast cancer patients suggests the ability of using serum S100A14 as a biomarker for detection of breast cancer metastasis.

The Study of Programmed Death-1 Receptor, Programmed Death-1 Ligand (Pd-1/Pd-L1) and Apoptosis in Breast Cancer Patients: A Potential Mechanism of Immune Escape

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 5-5
Author(s):  
S.A Ali ◽  
A.N El-Daly ◽  
A El-Sayed ◽  
H.G El-Shredy ◽  
G.A Fadaly
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Immune Escape ◽  
Serum Levels ◽  
Control Group ◽  
Potential Mechanism ◽  
Breast Cancer Patients ◽  
Programmed Death ◽  
Programmed Death 1

Introduction: The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest.However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to evaluate the role of programmed death-1 receptor and programmed death ligand-1 (PD-1/PD-L1) expressing lymphocytes, monocytes and granulocytes, as potential mechanism of immune escape in breast cancer patients. Also, serum levels of Bcl-2 were analyzed among patients with different stages of breast cancer. Material and Methods: The study was conducted on a total of seventy-five females; fifty-five of them represented the breast cancer females at early (24 females) and advanced (31 females) stages and 20 ages matched female donors represented the control group. Patients were recruited from the Cancer Research and Management Department, Medical Research Institute, Alexandria University. Venous blood samples obtained from all females under study were used for determination of PD-1/PD-L1 expression using flowcytometry technique and measurement of Bcl-2 serum levels using ELISA technique. Results: Significantly higher expression levels of PD-L1 were found in patients with positive lymph node, advanced tumor stage, histological grade II, tumor size T2, ER, PR, Her-2 negativity and TNBC subtype. Whilst a general increase in PD-1 positive expression between the breast cancer patients and control group regarding percentage and MFI of positive PD-1 expressing monocytes and granulocytes. Also, the results showed a highly significant association between PD-1+ and PD-L1+ expression in early and advanced breast cancer patients (p<0.0001). There was a significant increase in the mean of Bcl-2 serum concentration in patients compared to healthy individuals. Finally, the results showed that Bcl-2 serum concentration correlated positively with positive PD-L1+ expressing granulocytes. While the correlation between serum Bcl-2 and PD-1+ expressing lymphocytes, monocytes and granulocytes did not show any statistical significance. Conclusions: Our study suggested that PD-L1 could serve as an important target for antibody based immunotherapies, especially in the TNBC, where treatment options are limited. The direct correlation between PD-L1+ expression and serum Bcl-2 concentration may explore a role of apoptotic machinery in the pathogenesis of breast cancer.

scholarly journals Inherited thrombophilic risk factors in Serbian breast cancer patients

Genetika ◽  
2019 ◽  
Vol 51 (2) ◽  
pp. 463-472
Author(s):  
Iva Pruner ◽  
Branko Tomic ◽  
Marija Dragojevic ◽  
Maja Gvozdenov ◽  
Mirjana Kovac ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Cancer Susceptibility ◽  
Mthfr C677t ◽  
Control Group ◽  
Gene Variants ◽  
Breast Cancer Patients ◽  
Significant Difference

Breast cancer is the leading cause of cancer-related death among women. An increased burden of thrombotic events among breast cancer patients, leading to higher mortality and morbidity rates, is well established. There are a number of genetic risk factors associated with thrombosis, but their contribution to thrombotic tendencies in patients with cancer is not completely elucidated. We aimed to investigate possible role of FV Leiden, FII G20210A, MTHFR C677T and PAI-1 4G/5G gene variants in etiopathology of breast cancer and accompanying thrombosis in cohort of Serbian patients. Our study included 316 subject divided in three groups: breast cancer patients with (97) or without (99) accompanying thrombosis and healthy control group (120). According to our results, the prevalence for all four prothrombotic gene variants were similar in cancer patients with and without thrombosis and no statistically significant difference was observed between these groups. We detected lower frequency of MTHFR 677TT genotype in breast cancer patients when compared to control group (P=0.014; OR=0.145 (95%CI 0.031-0.679)), indicated that MTHFR C677T homozygosity could play a protective role in breast cancer susceptibility. Our study noted the lack of association between common prothrombotic gene variants and increased prothrombotic risk in Serbian breast cancer patients. Also, our results point out possible role of MTHFR 677TT genotype in etiology of breast cancer, but further studies on larger cohort of patients are needed.

Determination of Serum Angiopioetin-2 levels in Breast cancer patients at Damascus University Hospitals

2021 ◽  
pp. 4856-4858
Author(s):  
Majd Haidar ◽  
Jumana Al Saleh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Tumor Grade ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
University Hospitals ◽  
Healthy Control ◽  
Elisa Technique ◽  
Angiopoietin 2

Background: Breast cancer has increased universally. Angiogenesis is an essential step for cancer growth, progression and metastasis. Recent studies have focused on Angiopoietin-2 as a promising biomarker in prospecting the prognosis of the cancer. Objective: Determine the relation between serum concentrations of Angiopoietin-2 and clinicopathological data in breast cancer patients. Methodology: This study is prospective, cohort type. It includes 30 women with breast cancer, who met the study criteria. The serum Ang-2 value was calibrated using ELISA technique. The data was processed using SPSS program. Results: Ang-2 serum levels were statistically significant associated with ER status (P = 0.036). However, no signifi¬cant correlation was observed between serum Ang-2 level and the other clinicopathologic param¬eters tested, including Histological type (P = 0.417), Clinical grade G (P = 0.91), Clinical stage T (P = 0.913), Clinical stage N (P = 0.086), PR status (P = 0.467), and HER-2 status (P = 0.791). Serum levels of Ang-2 for breast cancer patients was significantly higher than healthy control (20411.33± 6283.19 vs 1731.70± 368.35 pg/ml, P< 0.000). our data indicates that serum levels of Ang-2 has no correlation between the tumor grade and stage in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document